Antibody-drug conjugates (ADCs) are transforming oncology treatment, delivering potent therapies with precision, delivering new hope in combating cancer by directly targeting malignant cells while minimizing damage to healthy tissue and achieving success in ADC manufacturing, means navigating a complex, multi-step development process.
At PCI, we believe that selecting the right CDMO for your new ADC is as important as selecting the right ADC components. As a partner, we offer stability, quality, strategic alignment and a forward-thinking approach in the development and manufacturing of your ADC product, supported by full, temperature-controlled packaging, storage and distribution services from our clinical packaging sites globally.
Three components to successfully developing ADCs
Integrated ADC Development Services include:
- Development, optimization and manufacturing services
- Process development, process optimization and scale up
- Formulation development (liquid and lyophilized) and drug product development
- Regulatory support
Analytical Capabilities for Development and Manufacturing
As a global leader of sterile fill-finish, lyophilization and high potent manufacturing services, a dedicated team will support your product lifecycle with method development, method optimization, method transfer and method qualification/validation.
For your ADC drug product release and stability testing stages, we provide you with access to our team, and a range of analytical services including:
Our dedicated team of specialists will be happy to discuss any of your Antibody Drug Conjugate Product needs. Contact us on +1 215-613-3600 (US) or +44 1495 711 222 (UK/EU) or email talkfuture@pci.com
Our antibody drug conjugate services
Latest resources
Article
February 14, 2025
Article
February 13, 2025
Article
February 13, 2025
Article
February 12, 2025